Chronic canine models of myocardial infarction and ventricular tachyarrhythmia are valuable preclinical tools for testing new antiarrhythmic drugs, as their electropharmacologic responses closely parallel those of human patients.
Supports chronic canine MI-VT models for preclinical antiarrhythmic screening in CAD; leaves open clinical translation pending prospective validation.
Several chronic canine myocardial infarction-ventricular tachyarrhythmia models are now available for the evaluation of new antiarrhythmic drugs. The available models fulfill many, but not all of the requirements for an ideal chronic arrhythmia model. Sustained arrhythmias can be initiated in these animals using routine methods of programmed pacing. Presumably, the mechanism for these arrhythmias is localized re-entry, similar to that in patients with previous myocardial infarction and chronic coronary artery disease. However, these models are not suitable for determining whether a new drug will abolish spontaneously-occurring ventricular extrasystoles. In addition, these models are of unproven value in the study of acute spontaneously-occurring sudden death, although recently initiated, provocative work may shed further light on this subject. Most importantly, the available models do seem well-suited to the evaluation of new drugs intended for use of chronic coronary artery disease patients at risk for sustained re-entrant ventricular tachycardia or fibrillation. Notably, the results of preliminary electropharmacologic studies in these canine models parallel closely those findings reported in human patients with sustained life-threatening ventricular tachyarrhythmias. Therefore, increased use of these chronic models for new antiarrhythmic drug testing appears promising.
No takes yet. Share an insight, caveat, or question.
Dreifus et al. (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: